Wedbush Has Strong Outlook for Disc Medicine FY2028 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Wedbush boosted their FY2028 EPS estimates for shares of Disc Medicine in a research note issued to investors on Tuesday, January 21st. Wedbush analyst D. Nierengarten now forecasts that the company will earn $7.51 per share for the year, up from their previous estimate of $7.04. Wedbush has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2029 earnings at $12.05 EPS.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a report on Tuesday, October 15th. Jefferies Financial Group initiated coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price for the company. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday. Finally, Scotiabank increased their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $88.20.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $60.52 on Wednesday. Disc Medicine has a one year low of $25.60 and a one year high of $77.60. The business’s 50-day moving average price is $62.82 and its two-hundred day moving average price is $53.66.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Amalgamated Bank lifted its stake in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after buying an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Disc Medicine by 2.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after acquiring an additional 771 shares during the period. SG Americas Securities LLC lifted its position in shares of Disc Medicine by 19.5% in the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock worth $239,000 after acquiring an additional 793 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in shares of Disc Medicine by 18.0% during the 3rd quarter. MetLife Investment Management LLC now owns 11,377 shares of the company’s stock worth $559,000 after purchasing an additional 1,735 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Disc Medicine

In other news, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total value of $470,625.00. Following the sale, the insider now owns 14,035 shares in the company, valued at approximately $880,696.25. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William Richard White sold 7,136 shares of the company’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Insiders sold 85,758 shares of company stock worth $5,400,990 over the last ninety days. Company insiders own 4.24% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.